While, in EUHER2 study [25], afatinib showed a modest response of 18.2% and median PFS of 3.9 months even though this drug has showed response in all 3 assessable patients with HER2-mutant adenocarcinoma in a preliminary study [28]. The gene discussed is ERBB2; the disease is adenocarcinoma.